Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Dietary Pyrophosphate Modulates Calcification in a Mouse Model of Pseudoxanthoma Elasticum: Implication for Treatment of Patients.

Pomozi V, Julian CB, Zoll J, Pham K, Kuo S, Tőkési N, Martin L, Váradi A, Le Saux O.

J Invest Dermatol. 2018 Nov 20. pii: S0022-202X(18)32826-4. doi: 10.1016/j.jid.2018.10.040. [Epub ahead of print]

PMID:
30468740
2.

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Le Saux O, Decullier E, Freyer G, Glehen O, Bakrin N.

Int J Hyperthermia. 2018 Oct 8:1-6. doi: 10.1080/02656736.2018.1518544. [Epub ahead of print]

PMID:
30295114
3.

ABCC6 Deficiency Promotes Development of Randall Plaque.

Letavernier E, Kauffenstein G, Huguet L, Navasiolava N, Bouderlique E, Tang E, Delaitre L, Bazin D, de Frutos M, Gay C, Perez J, Verpont MC, Haymann JP, Pomozi V, Zoll J, Le Saux O, Daudon M, Leftheriotis G, Martin L.

J Am Soc Nephrol. 2018 Sep;29(9):2337-2347. doi: 10.1681/ASN.2017101148. Epub 2018 Jul 10.

PMID:
29991491
4.

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.

Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15.

PMID:
29948022
5.

[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].

Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S.

Bull Cancer. 2018 Jul - Aug;105(7-8):686-695. doi: 10.1016/j.bulcan.2018.04.011. Epub 2018 Jun 20. Review. French.

PMID:
29933886
6.

Toxicity of Cancer Therapies in Older Patients.

Le Saux O, Falandry C.

Curr Oncol Rep. 2018 Jun 13;20(8):64. doi: 10.1007/s11912-018-0705-y. Review.

PMID:
29896642
7.

Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology.

Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotté F, Bellmunt J, Launay-Vacher V.

Lancet Oncol. 2018 Jun;19(6):e317-e326. doi: 10.1016/S1470-2045(18)30125-6. Epub 2018 Jun 1. Review.

PMID:
29893263
8.

PATHOGENIC VARIANTS IN THE ABCC6 GENE ARE ASSOCIATED WITH AN INCREASED RISK FOR ISCHEMIC STROKE.

De Vilder EYG, Cardoen S, Hosen MJ, Le Saux O, De Zaeytijd J, Leroy BP, De Reuck J, Coucke PJ, De Paepe A, Hemelsoet D, Vanakker OM.

Brain Pathol. 2018 May 3. doi: 10.1111/bpa.12620. [Epub ahead of print]

PMID:
29722917
9.

Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation.

Bauer C, le Saux O, Pomozi V, Aherrahrou R, Kriesen R, Stölting S, Liebers A, Kessler T, Schunkert H, Erdmann J, Aherrahrou Z.

Sci Rep. 2018 Apr 11;8(1):5812. doi: 10.1038/s41598-018-24228-y.

10.

Systematic review of care needs for older patients treated with anticancer drugs.

Le Saux O, Lapotre-Aurelle S, Watelet S, Castel-Kremer E, Lecardonnel C, Murard-Reeman F, Ravot C, Falandry C.

J Geriatr Oncol. 2018 Sep;9(5):441-450. doi: 10.1016/j.jgo.2018.02.009. Epub 2018 Mar 21.

PMID:
29573968
11.

Alteration of Extracellular Nucleotide Metabolism in Pseudoxanthoma Elasticum.

Kauffenstein G, Yegutkin GG, Khiati S, Pomozi V, Le Saux O, Leftheriotis G, Lenaers G, Henrion D, Martin L.

J Invest Dermatol. 2018 Aug;138(8):1862-1870. doi: 10.1016/j.jid.2018.02.023. Epub 2018 Mar 6.

PMID:
29501384
12.

Reply to "Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations" by Mislang et al.

Le Saux O, Ravot C, Castel-Kremer E, Falandry C.

J Geriatr Oncol. 2018 Sep;9(5):540-541. doi: 10.1016/j.jgo.2018.01.010. Epub 2018 Feb 14. No abstract available.

PMID:
29454825
13.

Is There an Age Threshold for Holding Off on Testing Novel Therapies?

Le Saux O, Falandry C.

Curr Oncol Rep. 2018 Feb 7;20(1):6. doi: 10.1007/s11912-018-0663-4. Review.

PMID:
29411123
14.

Assessing capacity to consent for research in cognitively impaired older patients.

Gilbert T, Bosquet A, Thomas-Antérion C, Bonnefoy M, Le Saux O.

Clin Interv Aging. 2017 Sep 26;12:1553-1563. doi: 10.2147/CIA.S141905. eCollection 2017. Review.

15.

Changes in the use of end points in clinical trials for elderly cancer patients over time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2017 Oct 1;28(10):2606-2611. doi: 10.1093/annonc/mdx354.

PMID:
28961850
16.

The ABCC6 Transporter: A New Player in Biomineralization.

Favre G, Laurain A, Aranyi T, Szeri F, Fulop K, Le Saux O, Duranton C, Kauffenstein G, Martin L, Lefthériotis G.

Int J Mol Sci. 2017 Sep 11;18(9). pii: E1941. doi: 10.3390/ijms18091941. Review.

17.

Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.

PMID:
28890328
18.

Oral administration of pyrophosphate inhibits connective tissue calcification.

Dedinszki D, Szeri F, Kozák E, Pomozi V, Tőkési N, Mezei TR, Merczel K, Letavernier E, Tang E, Le Saux O, Arányi T, van de Wetering K, Váradi A.

EMBO Mol Med. 2017 Nov;9(11):1463-1470. doi: 10.15252/emmm.201707532.

19.

Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.

Pomozi V, Brampton C, van de Wetering K, Zoll J, Calio B, Pham K, Owens JB, Marh J, Moisyadi S, Váradi A, Martin L, Bauer C, Erdmann J, Aherrahrou Z, Le Saux O.

Am J Pathol. 2017 Jun;187(6):1258-1272. doi: 10.1016/j.ajpath.2017.02.009. Epub 2017 Apr 14.

20.

Functional Rescue of ABCC6 Deficiency by 4-Phenylbutyrate Therapy Reduces Dystrophic Calcification in Abcc6-/- Mice.

Pomozi V, Brampton C, Szeri F, Dedinszki D, Kozák E, van de Wetering K, Hopkins H, Martin L, Váradi A, Le Saux O.

J Invest Dermatol. 2017 Mar;137(3):595-602. doi: 10.1016/j.jid.2016.10.035. Epub 2016 Nov 5.

21.

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29.

PMID:
27358382
22.

First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.

Le Saux O, Freyer G, Négrier S.

Clin Drug Investig. 2016 May;36(5):389-99. doi: 10.1007/s40261-016-0384-0. Review.

PMID:
26945986
23.

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France.

Le Saux O, Taylor A, Chia V, Pillas D, Kaur M, Freyer G.

Clin Epidemiol. 2015 Oct 27;7:431-40. doi: 10.2147/CLEP.S86429. eCollection 2015.

24.

Optimal management of breast cancer in the elderly patient: current perspectives.

Le Saux O, Ripamonti B, Bruyas A, Bonin O, Freyer G, Bonnefoy M, Falandry C.

Clin Interv Aging. 2015 Jan 6;10:157-74. doi: 10.2147/CIA.S50670. eCollection 2015. Review.

25.

The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum.

Leftheriotis G, Kauffenstein G, Hamel JF, Abraham P, Le Saux O, Willoteaux S, Henrion D, Martin L.

PLoS One. 2014 May 6;9(5):e96003. doi: 10.1371/journal.pone.0096003. eCollection 2014.

26.

Perturbation of specific pro-mineralizing signalling pathways in human and murine pseudoxanthoma elasticum.

Hosen MJ, Coucke PJ, Le Saux O, De Paepe A, Vanakker OM.

Orphanet J Rare Dis. 2014 Apr 29;9:66. doi: 10.1186/1750-1172-9-66.

27.

Disseminated arterial calcification and enhanced myogenic response are associated with abcc6 deficiency in a mouse model of pseudoxanthoma elasticum.

Kauffenstein G, Pizard A, Le Corre Y, Vessières E, Grimaud L, Toutain B, Labat C, Mauras Y, Gorgels TG, Bergen AA, Le Saux O, Lacolley P, Lefthériotis G, Henrion D, Martin L.

Arterioscler Thromb Vasc Biol. 2014 May;34(5):1045-56. doi: 10.1161/ATVBAHA.113.302943. Epub 2014 Mar 27. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):e16.

28.

The level of hepatic ABCC6 expression determines the severity of calcification after cardiac injury.

Brampton C, Aherrahrou Z, Chen LH, Martin L, Bergen AA, Gorgels TG, Erdmann J, Schunkert H, Szabó Z, Váradi A, Le Saux O.

Am J Pathol. 2014 Jan;184(1):159-70. Erratum in: Am J Pathol. 2014 Mar;184(3):878. Erdfdi, Jeannette [corrected to Erdmann, Jeannette].

29.

Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.

Le Saux O, You B, Freyer G.

Clin Breast Cancer. 2014 Jun;14(3):e89-94. doi: 10.1016/j.clbc.2013.11.005. Epub 2013 Nov 21. No abstract available.

PMID:
24424314
30.

Analysis of pseudoxanthoma elasticum-causing missense mutants of ABCC6 in vivo; pharmacological correction of the mislocalized proteins.

Pomozi V, Brampton C, Fülöp K, Chen LH, Apana A, Li Q, Uitto J, Le Saux O, Váradi A.

J Invest Dermatol. 2014 Apr;134(4):946-953. doi: 10.1038/jid.2013.482. Epub 2013 Nov 11.

31.

Pseudoxanthoma elasticum: cardiac findings in patients and Abcc6-deficient mouse model.

Prunier F, Terrien G, Le Corre Y, Apana AL, Bière L, Kauffenstein G, Furber A, Bergen AA, Gorgels TG, Le Saux O, Leftheriotis G, Martin L.

PLoS One. 2013 Jul 23;8(7):e68700. doi: 10.1371/journal.pone.0068700. Print 2013.

32.

High-frequency (20-50 MHz) ultrasonography of pseudoxanthoma elasticum skin lesions.

Guérin-Moreau M, Leftheriotis G, Le Corre Y, Etienne M, Amode R, Hamel JF, Croué A, Le Saux O, Machet L, Martin L.

Br J Dermatol. 2013 Dec;169(6):1233-9. doi: 10.1111/bjd.12545.

33.

ABCC6 is a basolateral plasma membrane protein.

Pomozi V, Le Saux O, Brampton C, Apana A, Iliás A, Szeri F, Martin L, Monostory K, Paku S, Sarkadi B, Szakács G, Váradi A.

Circ Res. 2013 May 24;112(11):e148-51. doi: 10.1161/CIRCRESAHA.111.300194. Epub 2013 Apr 26.

34.

Transcriptional regulation of the ABCC6 gene and the background of impaired function of missense disease-causing mutations.

Arányi T, Bacquet C, de Boussac H, Ratajewski M, Pomozi V, Fülöp K, Brampton CN, Pulaski L, Le Saux O, Váradi A.

Front Genet. 2013 Mar 11;4:27. doi: 10.3389/fgene.2013.00027. eCollection 2013.

35.

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

Hamizi S, Freyer G, Bakrin N, Henin E, Mohtaram A, Le Saux O, Falandry C.

Onco Targets Ther. 2013;6:89-94. doi: 10.2147/OTT.S27733. Epub 2013 Feb 14.

36.

The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification.

Lefthériotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, Willoteaux S, Martin L.

Front Genet. 2013 Feb 12;4:4. doi: 10.3389/fgene.2013.00004. eCollection 2013.

37.

The molecular and physiological roles of ABCC6: more than meets the eye.

Le Saux O, Martin L, Aherrahrou Z, Leftheriotis G, Váradi A, Brampton CN.

Front Genet. 2012 Dec 12;3:289. doi: 10.3389/fgene.2012.00289. eCollection 2012.

38.

Quantification of the calcification phenotype of Abcc6-deficient mice with microcomputed tomography.

Le Corre Y, Le Saux O, Froeliger F, Libouban H, Kauffenstein G, Willoteaux S, Leftheriotis G, Martin L.

Am J Pathol. 2012 Jun;180(6):2208-13. doi: 10.1016/j.ajpath.2012.02.007. Epub 2012 Mar 31.

39.

Expression and in vivo rescue of human ABCC6 disease-causing mutants in mouse liver.

Le Saux O, Fülöp K, Yamaguchi Y, Iliás A, Szabó Z, Brampton CN, Pomozi V, Huszár K, Arányi T, Váradi A.

PLoS One. 2011;6(9):e24738. doi: 10.1371/journal.pone.0024738. Epub 2011 Sep 14.

40.

Relationship between ankle brachial index and arterial remodeling in pseudoxanthoma elasticum.

Lefthériotis G, Abraham P, Le Corre Y, Le Saux O, Henrion D, Ducluzeau PH, Prunier F, Martin L.

J Vasc Surg. 2011 Nov;54(5):1390-4. doi: 10.1016/j.jvs.2011.04.041. Epub 2011 Jul 1.

41.

Vitamin K does not prevent soft tissue mineralization in a mouse model of pseudoxanthoma elasticum.

Brampton C, Yamaguchi Y, Vanakker O, Van Laer L, Chen LH, Thakore M, De Paepe A, Pomozi V, Szabó PT, Martin L, Váradi A, Le Saux O.

Cell Cycle. 2011 Jun 1;10(11):1810-20. Epub 2011 Jun 1.

42.

Reply to the article of C. Markello et al. entitled "Vascular pathology of medial arterial calcifications in NT5E deficiency: Implications for the role of adenosine in pseudoxanthoma elasticum".

Lefthériotis G, Vanakker O, Le Saux O, Martin L.

Mol Genet Metab. 2011 Jun;103(2):199-200. doi: 10.1016/j.ymgme.2011.03.014. Epub 2011 Mar 24. No abstract available.

43.

A mouse model of β-thalassemia shows a liver-specific down-regulation of Abcc6 expression.

Martin L, Douet V, VanWart CM, Heller MB, Le Saux O.

Am J Pathol. 2011 Feb;178(2):774-83. doi: 10.1016/j.ajpath.2010.10.004.

44.

Novel deletions causing pseudoxanthoma elasticum underscore the genomic instability of the ABCC6 region.

Costrop LM, Vanakker OO, Van Laer L, Le Saux O, Martin L, Chassaing N, Guerra D, Pasquali-Ronchetti I, Coucke PJ, De Paepe A.

J Hum Genet. 2010 Feb;55(2):112-7. doi: 10.1038/jhg.2009.132. Epub 2010 Jan 15.

PMID:
20075945
45.

The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties.

Le Saux O, Teeters K, Miyasato S, Choi J, Nakamatsu G, Richardson JA, Starcher B, Davis EC, Tam EK, Jourdan-Le Saux C.

Am J Physiol Lung Cell Mol Physiol. 2008 Dec;295(6):L1007-17. doi: 10.1152/ajplung.90207.2008. Epub 2008 Oct 10.

46.

Heterozygosity for a single mutation in the ABCC6 gene may closely mimic PXE: consequences of this phenotype overlap for the definition of PXE.

Martin L, Maître F, Bonicel P, Daudon P, Verny C, Bonneau D, Le Saux O, Chassaing N.

Arch Dermatol. 2008 Mar;144(3):301-6. doi: 10.1001/archderm.144.3.301.

PMID:
18347285
47.

DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter.

Douet V, Heller MB, Le Saux O.

Biochem Biophys Res Commun. 2007 Mar 2;354(1):66-71. Epub 2006 Dec 28.

48.

[Increased haemoglobin A2 levels in pseudoxanthoma elasticum].

Martin L, Pissard S, Blanc P, Chassaing N, Legac E, Briault S, Le Bert M, Le Saux O.

Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):645-51. French.

PMID:
17053732
49.

HNF4alpha and NF-E2 are key transcriptional regulators of the murine Abcc6 gene expression.

Douet V, VanWart CM, Heller MB, Reinhard S, Le Saux O.

Biochim Biophys Acta. 2006 Aug-Sep;1759(8-9):426-36. Epub 2006 Aug 11.

50.

Serum factors from pseudoxanthoma elasticum patients alter elastic fiber formation in vitro.

Le Saux O, Bunda S, VanWart CM, Douet V, Got L, Martin L, Hinek A.

J Invest Dermatol. 2006 Jul;126(7):1497-505. Epub 2006 Mar 16.

Supplemental Content

Loading ...
Support Center